title: Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy.
abstract: BACKGROUND
  The proto-oncogene pituitary tumor-transforming gene (PTTG) is described as abundantly over-expressed in a variety of neoplasms with impact on neovascularization and tumor invasiveness. Based on these findings, we raised the question as to whether PTTG is a target for an anti-tumor therapy.
  
  
  METHODS
  To investigate the impact of PTTG depletion on the human cervical cancer cell line HELA-S3, we used antisense-oligodesoxynucleotides (antisense-ODNs) and subjected them to in vitro transfection experiments. The PTTG mRNA level was determined by RT-PCR (45 cycles) and PTTG protein levels were determined by Western blot experiments. The impact of PTTG depletion on cell growth was determined 24, 48 and 72 hours post transfection by the trypan blue exclusion method.
  
  
  RESULTS
  We found an antisense-ODN effective in down-regulation of PTTG mRNA and protein level. Furthermore, transfection resulted in a significant growth inhibitory effect as well as an increased level of apoptotic figures.
  
  
  CONCLUSIONS
  Our studies revealed an anti-tumor potential for this target in cancer therapy.
authors.affiliation: Department of Gynecology and Obstetrics, Johann Wolfgang Goethe University, School of Medicine, Frankfurt am Main, Germany. Solbach@em.uni-frankfurt.de
authors.forename: Christine
authors.initials: C
authors.lastname: Solbach
authors.forename: Marc
authors.initials: M
authors.lastname: Roller
authors.forename: Silke
authors.initials: S
authors.lastname: Peters
authors.forename: Maria
authors.initials: M
authors.lastname: Nicoletti
authors.forename: Manfred
authors.initials: M
authors.lastname: Kaufmann
authors.forename: Rainald
authors.initials: R
authors.lastname: Knecht
mesh_terms: D048708:Cell Growth Processes / Q000235:genetics; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006367:HeLa Cells; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics*; D016376:Oligonucleotides, Antisense / Q000235:genetics*; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger / Q000096:biosynthesis / Q000378:metabolism; D064249:Securin; D014162:Transfection; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*
chemical_list: C000715470:MAS1 protein, human; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger; D064249:Securin; C578002:pituitary tumor-transforming protein 1, human